Sorafenib in Treating Patients With Advanced Solid Tumors

Inclusion Criteria: * Histologically or cytologically confirmed malignant solid tumor * Refractory disease for which curative or palliative measures have failed or for which there is no known superior treatment * No colorectal cancer or melanoma * Measurable OR nonmeasurable disease * Normotensive (blood pressure \[BP\] ≤ 140/90 mm Hg) meeting 1 of the following criteria: * No more than 2 attempted measurement sessions for which the documented mean systolic BP is ≤ 140 mm Hg and the diastolic BP is ≤ 90 mm Hg * At least 30 attempted measurement sessions for which the documented mean systolic BP is ≤ 135 mm HG and the diastolic BP is ≤ 85 mm Hg * Brain metastases allowed provided the following criteria are met: * Stable neurologic status for ≥ 2 weeks after completion of definitive local therapy (surgery or radiotherapy) * No neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * ECOG performance status 0-1 * Life expectancy \> 12 weeks * Age ≥ 14 years OR weight ≥ 45 kilograms (pediatric patients) * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Hemoglobin ≥ 8.5 g/dL * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * AST and ALT ≤ 2.5 times ULN (5 times ULN if there is liver involvement) * Creatinine ≤ 1.5 times ULN * No New York Heart Association class II-IV congestive heart failure * No unstable angina (anginal symptoms at rest) or new-onset angina (began within the past 3 months) * No myocardial infarction within the past 6 months * No ventricular arrhythmias requiring anti-arrhythmic therapy * No thrombotic or embolic events, such as symptomatic pulmonary embolus or any cerebrovascular accident (including transient ischemic attacks) within the past 6 months * No pulmonary hemorrhage/bleeding event \> grade 2 within the past 4 weeks * No other hemorrhage/bleeding event \> grade 3 within the past 4 weeks * No evidence or history of bleeding diathesis or coagulopathy * No serious nonhealing wound, ulcer, or bone fracture * No ongoing or active infection \> grade 2 * No psychiatric illness or social situation that would limit compliance with study requirements * No allergy to sorafenib tosylate or excipients * No unstable condition that would jeopardize the safety of the patient and/or her/his compliance with the study * No significant traumatic injury within the past 4 weeks * No condition that would impair the patient's ability to swallow whole pills or capacity to absorb oral medications * No seizure disorder requiring steroids or anticonvulsant therapy * No other concurrent illness * Recovered from prior therapy * Prior vascular endothelial growth factor (VEGF) pathway inhibitor (e.g., bevacizumab, sunitinib malate, axitinib) allowed provided the following criteria are met: * The patient's best response as measured by RECIST criteria was not progressive disease * If the most recent agent was a small molecule reversible inhibitor (e.g., sunitinib malate, cediranib, or axitinib), the patient must not have taken a dose of the agent within 2 weeks of the baseline blood pressure session and 3 weeks of starting sorafenib tosylate * If the most recent agent was bevacizumab or VEGF trap the patient must not have received the most recent dose within 5 weeks of the baseline blood pressure session and 6 weeks of starting sorafenib tosylate AND no grade 3 bleeding, cardiovascular, skin, or thyroid toxicities on one of these previous therapies * More than 2 weeks since prior and no concurrent radiotherapy * At least 3 weeks since prior and no concurrent chronic epoetin alfa (or congeners) * More than 3 weeks since prior immunotherapy or chemotherapy (6 weeks for nitrosoureas or mitomycin C) * More than 4 weeks since prior major surgery or open biopsy * At least 3 weeks since prior uncharacterized herbal agents or nutritional supplements * More than 12 weeks since prior radioimmunotherapy * No prior sorafenib tosylate * No prior organ allograft or allogeneic bone marrow or peripheral blood stem cell transplantation * Patients with a history of autologous transplant and normal bone marrow function are eligible * No prior cyclosporine, Hypericum perforatum (St. John's wort), or rifampin * No other concurrent investigational agents * No other concurrent antineoplastic therapy, including chemotherapy, except androgen-ablating agents (for patients with prior prostate cancer) * No concurrent hematopoietic growth factors * No concurrent combination antiretroviral therapy for HIV-positive or chronic hepatitis B-positive patients * No concurrent hormonal therapy except steroids for adrenal insufficiency or hormones for nondisease-related conditions (e.g., insulin for diabetes) * Steroids for autoimmune cytopenia allowed provided dose has been stable for 3 weeks * No anticipated need for other antineoplastic therapy within the next 4 weeks